U.S. markets closed

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
88.71+4.99 (+5.96%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close83.72
Open86.72
Bid87.38 x 900
Ask89.90 x 1200
Day's Range86.41 - 90.64
52 Week Range31.11 - 92.60
Volume1,568,346
Avg. Volume728,070
Market Cap9.233B
Beta (5Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Arrowhead Receives $10M Option Exercise Fee From Janssen
    Benzinga

    Arrowhead Receives $10M Option Exercise Fee From Janssen

    Janssen Pharmaceuticals Inc, part of Johnson & Johnson (NYSE: JNJ), has delivered written notice of its intent to exercise its option right for ARO-JNJ1. Receipt of the option notice earns Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) a $10 million option exercise fee. Janssen will now have all rights to develop and commercialize ARO-JNJ1, an investigational RNAi therapeutic candidate which utilizes Arrowhead's proprietary Targeted RNAi Molecule platform. "The collaboration with Janssen, which was executed in 2018, for ARO-HBV against chronic hepatitis B infection, and potentially three additional programs, has been highly productive and collaborative," said Chris Anzalone, President & CEO at Arrowhead. Price Action: JNJ shares are down 0.22% at $170.02 during the premarket session on the last check Tuesday. ARWR closed at $73.05 on Monday. See more from BenzingaClick here for options trades from BenzingaUS Poised To Dispatch 20M Additional COVID-19 Shots To Countries In Need: CNBCJ&J Cuts This Week's COVID-19 Vaccine Deliveries For EU By Half: Reuters© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
    Simply Wall St.

    Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

    How far off is Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) from its intrinsic value? Using the most recent...

  • Arrowhead Pharmaceuticals, Inc (ARWR) Q2 2021 Earnings Call Transcript
    Motley Fool

    Arrowhead Pharmaceuticals, Inc (ARWR) Q2 2021 Earnings Call Transcript

    ARWR earnings call for the period ending March 31, 2021.